Dual-action cancer nanomedicine therapy

Scientists have fabricated antibody-coated porous silicon nanoparticles that can actively target cells through binding to specific cell-surface receptors. These nanoparticles were demonstrated to selectively deliver multiple therapeutics to human B cells in vitro.